Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises by Yang, M. et al.
sustainability
Article
Does CSR Influence Firm Performance Indicators?
Evidence from Chinese Pharmaceutical Enterprises
Minghui Yang 1 , Paulo Bento 2 and Ahsan Akbar 1,*
1 International Business School, Guangzhou College of South China University of Technology,
Guangzhou 510800, China; yangmh@gcu.edu.cn
2 ISCTE Business School, University Institute of Lisbon, 1649-026 Lisbon, Portugal; paulo.bento@iscte.pt
* Correspondence: akbar@gcu.edu.cn
Received: 9 August 2019; Accepted: 8 October 2019; Published: 14 October 2019


Abstract: This research is carried out in the backdrop of increasing product quality and environmental
degradation scandals associated with Chinese Pharmaceuticals in recent years. We examined the data
of 125 Chinese Pharmaceuticals between 2010–2016 to investigate the impact of overall corporate
social responsibility (CSR) performance as well as the performance on five unique aspects of CSR
such as shareholders, employees, customers and suppliers, environmental practices, and the society
to gauge the impact of these individual dimensions on the firm’s financial performance. The Hexun
rating system is used to gauge a firm’s CSR performance on various stakeholder dimensions as it is
one of the widely accepted CSR measurement criteria in China. The firm performance is measured
by Tobin’s Q, return on assets (ROA), return on equity (ROE), and earnings per share (EPS) ratios.
The outcome of the panel-based regression models reveals that the overall CSR score has a positive and
significant influence on a firm’s financial indicators. Moreover, although all the CSR dimensions relate
positively to firm performance, the environmental aspect of CSR has the most profound impact on
firm performance followed by customers and suppliers, and employees. However, the shareholders
and social dimensions have a relatively lesser influence on firm performance. These results imply
that Chinese Pharmaceuticals shall further optimize each aspect of CSR performance as it can
not only create a favorable brand image for various stakeholders but also results in sustainable
financial performance.
Keywords: CSR dimensions; chinese pharmaceuticals; mixed-method approach; firm performance
1. Introduction
Corporate social responsibility (CSR) has gained momentum as a critical issue for many firms
because of the increase in public awareness about the impact of corporate activities on the environment
and society [1]. Companies are expected to act in a socially responsible manner as well as be financially
accountable [2]. Recently, CSR evokes public attention in China because of the increasing number
of incidents concerning product safety and environmental pollution. The widespread perception
of lacking social responsibility in Chinese firms has become a primary driver for CSR expansion in
China [3].
The improvement in firm performance is a critical factor for firms to decide whether or not to
implement particular organizational policies and practices [4]. Prior literature has not yet reached a
consensus on the nature of the relationship between CSR and firm performance [5,6]. Disagreements
on the adoption of CSR still persist, reflecting the higher costs of CSR practices which may contradict
the primary goal of profit maximization [7,8]. Notwithstanding, recent empirical studies suggest that
CSR is beneficial for firm performance by enhancing employee satisfaction, attracting ethical customers,
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and building a better corporate image [9,10]. However, this positive association might not prevail
during the course of a financial crisis as witnessed during the U.S. financial turmoil of 2008 [11].
The dilemma of CSR promotion is more evident in corporate China, where economic motives are
highly emphasized in CSR-related decision making [12]. Based on the analysis of 1533 media reports
concerning food safety scandals, Zhang and Xue [13] exposit that economically motivated frauds were
a serious and emerging food safety issue in China. Given the increasing demand for high-quality
drugs and reliable medical services, pharmaceutical firms are financially challenged in the global
markets [14]. Undoubtedly, medication is directly associated with people’s well-being. The popularity
of environmentalism, the increased buying power, and the globalization of medical business also led
to the spread of CSR practices in the context of the pharmaceutical industry [15,16]. Unlike other
industries, there is a difference of opinion about the positive effects of CSR related investment on the
performance of Chinese pharmaceuticals. Pharmaceutical firms usually feel reluctant to implement
costly CSR practices partly due to excessive resources assigned to R&D and the promotional activities
required in this type of business [17].
Product-Related Incidents in Chinese Pharmaceuticals
Wang and Xu [17] contend that the CSR performance of Chinese Pharmaceuticals receives special
attention from various stakeholders for the following reasons:
The first rationale is about responsibility for product quality. The quality of drug-related products
and services corresponds to human health, which is critical in the public eye. This responsibility
includes the reliability of drug information disclosure and the safety of product treatments.
Pharmaceutical companies should take care of low-income groups by providing high-quality products
at affordable prices.
The second reason is concerned with responsibility toward the supply chain. Pharmaceutical
companies should ensure the safety and quality of raw materials deployed in the manufacturing
process. Additionally, the safety and reliability of the R&D process should also be taken into
consideration. Thirdly, Advertising for drug-related products and services should be reliable and
not unrealistic. Pharmaceutical companies should also supervise and control products’ promotional
activities. Fourthly, Pharmaceutical companies are obligated to educate local communities for disease
prevention and the safe use of drugs. In addition, pharmaceutical firms need to intensify collaboration
with local groups and associations in terms of health training.
Fifthly, such firms shall take full responsibility toward recycling of expired drugs. Expired drugs
have considerable side-effects that may be harmful to human health and the surrounding environment.
It is essential for pharmaceutical companies to establish an effective supervisory system to control
recalls for medications as well as disposal of outdated drugs. Lastly, the pharmaceutical company
should deliver clinical and trial tests in safe ways and supervise medical tests before the new launch of
drug-related products and services.
In the last decade, there have been several critical incidents involving drug-related products or
services in China. Table 1 illustrates the incidents of China’s pharmaceutical companies between 2006
and 2017 [18].
This paper delves into the CSR performance data of Chinese pharmaceutical companies from the
Hexun CSR database, which consists of 38 measures over five dimensions of CSR practices between
2010 and 2016. The weight of each CSR dimension namely shareholders, employees, customers and
suppliers, environmental practices, and society is taken from the Hexun CSR rating system as it is the
most trusted source of CSR evaluation in China. Subsequently, the panel-based regression models are
developed to test the corresponding hypotheses. Each CSR dimension was regressed with the firm
performance indicators to adequately address the research questions raised in this study.
The present study examines whether CSR activities are a way for Chinese Pharmaceuticals to
improve their financial performance. The study makes the following contributions to the extant
literature on CSR. First, unlike previous studies, which take the overall Hexun CSR score to proxy
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the firm’s CSR performance, we employ econometric models on each CSR dimension to assess the
significance of a particular dimension in impacting the firm’s financial fundamentals. Second, owing
to the unique business model, pharmaceuticals have a direct influence on environmental quality and
public well-being. Nevertheless, such firms have to allocate more resources to R&D and promotional
activities, leaving fewer funds to actively engage in CSR practices. This unique business model
makes it very interesting to investigate how pharmaceutical firms manage this trade-off and their
perception of CSR. Third, in the backdrop of numerous product quality scandals reported in the Chinese
pharmaceutical industry in recent years, it is essential to explore the managerial attitude towards the
CSR activities and its perceived impact on firm performance in this particular industry setting.
Table 1. Drug-related product incidents in China, 2006–2019.
Date Incident Consequence
2019 Explosion in glutamine manufacturing line ofShenhua Pharma in Jiangsu Province.
Eight persons were severely injured, one
person died.
2018 Injurious hydrophobia vaccine made by ChangshengPharma in the Jilin Province.
All vaccines were not sold yet, 15 criminals
including senior management were arrested.
2017 False DPT (Diphtheria, Pertussis, Tetanus) vaccinemade by Changsheng Pharma in the Jilin Province.
252,600 vaccines confiscated in the
Shangdong Province.
2017 Misleading advertising for eye drops by SPAS. There was a significant drop in share price by40% within a week.
2016 Injurious vaccine made by an illegal medical factoryin the Shandong Province
Vaccines spread into over 10 provinces and
some children were infected.
2014 Counterfeit drugs to treat diabetes manufactured inthe Henan Province. Several patients were affected.
2013 Injurious vaccine from Kangtai Pharma in theGuangdong Province.
Seven newborn babies died. Deaths were
suspected to be caused by the vaccine.
2012 Toxic capsules made by Hengtai Pharma in theJiangsu Province.
Thirteen batches of capsules had excessive
chromium.
2011 Plasticizer scandal in Taiwan. It spread to 294 companies and a total of 973different products.
2009 Poor quality of Coptis chinensis injection in theHeilongjiang Province. One death was reported in this incident.
2008 Injurious vaccine made by Huawei Pharma in theShanxi Province. One death was reported in this incident.
2006 Visible particles existed in glucose and sodiumchloride injections in the Hebei Province.
Nine patients were affected and adverse
reactions occurred.
Source: Website of China Food and Drug Administration (2019).
The rest of the paper is organized as follows. Section 2 elaborates the literature review and
develops corresponding hypotheses. Section 3 describes the data and methodology. Section 4 reports
results of analysis and unfolds discussions. Section 5 concludes the study.
2. Literature Review and Hypotheses Development
2.1. Evolution of CSR
CSR was initially proposed by Shelton in 1924. He argued that preserving the interests of society
is the main responsibility of an enterprise while it pursues the profit motive [19]. The uprising phase
of CSR began in 1950 when Bowen defined CSR as an obligation that businessmen need to follow
under the values of a society. The idea of CSR further evolved in 1960 as there was a movement
towards environmental protection, customers’ rights, and women rights. Frederick [20] suggested
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that firms need to enhance socioeconomic welfare and fulfill the expectations of the general public.
David [21] extended CSR to the moral standpoint and stated that CSR is the right thing for firms to
do. In 1970 the scope of CSR was further elaborated by scholars and organizations. For instance,
Johnson [22] proposed that the dimensions of CSR encompass employees, suppliers, dealers, local
community, and the government. The Committee for Economic Development (CED) also elucidated
the CSR concept through three concentric circles. The inner circle depicts the core functions such
as economic growth and job satisfaction. The intermediate circle concerns the responsiveness such
as environmental protection and information disclosure of CSR activities. The outer circle relates
to the well-being of society and ecosystem such as eradicating poverty and urban blight issues [23].
Undoubtedly, the most well-known definition was proposed by Carroll [24], who regarded CSR as the
sum of obligation that society expects firms to fulfill. He outlined the three-dimensional conceptual
model of corporate social performance. Later, the CSR concept was extended to a four-dimensional
model comprising of the economic, legal, ethical, and discretionary dimensions.
The well-known stakeholder theory proposed by Freeman [25] was propagated in 1984.
Stakeholder theory suggests that managers need to focus on the groups who influence and are
influenced by an enterprise’s business activities. Managing relationships with stakeholders, such as
stockholders, employees, customers, and community, etc., is imperative for a firm to reach success.
CSR relates to the way a company treats stakeholders in terms of moral obligation. Carroll [24] stated
that stakeholder theory can explain the motivation of CSR practices, and this is a promising theory to
“match” the CSR concept. Not surprisingly, stakeholder theory has been one of the most commonly
used notions in CSR literature. In 1990, the focus of CSR shifted to more pragmatic issues [26].
Specifically, scholars tried to link CSR benefits to practical business cases and attempted to address the
tangible gains an enterprise may collect from CSR engagement [27]. During the late 1990s, researchers
were inclined to incorporate CSR into strategic management so as to establish a connection between
the concept and the market outcome [28]. Scholars attempted to associate the CSR strategy with the
business strategy level and figure out how a firm could achieve both financial and social benefits for
its stakeholders to ensure competitiveness [29]. Since the 20th century, the development of value
creation took place in the CSR field. In particular, CSR practices enable companies to add value, such
as attracting valuable human resources, cultivating firm image, and so on [30]. Another movement
of CSR in the new millennium was the concern for sustainability. CSR was treated as an enterprise’s
commitment to maximize long-term positive effects and minimize negative impacts on society [31].
Consequently, CSR practices can be embraced as a key component in organizational objectives in order
to achieve sustainability [32]. The evolution of CSR is presented in Figure 1.Sustainability 2019, 11, x FOR PEER REVIEW 5 of 18 
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2.2. CSR in China
The extant literature primarily focused on CSR practices implemented by companies in advanced
economies, such as the U.S. and Europe [33,34]. However, few studies have focused on how CSR
is perceived and practiced in the emerging economies [4,35]. Admittedly, different institutional
environments in terms of a variety of social norms, culture, and traditions may impact CSR practices
through the underlying social expectation and public opinion pressures [36]. In addition, countries
at different phases of economic development have varied concerns and priorities, indicating that
developed countries have an entirely different understanding of CSR application in corporations than
their developing country counterparts [16,34]. In the context of emerging economies, there is a need for
appropriate frameworks to evaluate CSR performance accurately. Companies in developing economies
are less likely to conform to internationally recognized CSR principles and standards. Besides, such
firms would regard financial responsibility as a primary obligation, followed by philanthropic, legal,
and other discretionary obligations, respectively [37].
Due to the emergence of several scandals about Chinese companies regarding environmental
and product safety accidents, CSR has become the focal point of attention for academia, government,
and Chinese enterprises. Given the rapid expansion in both the economy and social awareness,
the Chinese government plays a vital role in examining and regulating CSR practices, aiming to balance
economic growth with social development. The first policy initiative concerning CSR practices is the
Company Law which was rolled out in 1994. It explicitly concerns the protection of employee’s rights
in enterprises [38]. The 2006 Company Law supplements the definition of CSR in Article 5 by stating
that CSR is an obligation that the companies are obligated to comply with in order to promote social
morality and business ethics under governmental supervision [39]. Given the widespread participation
of state-owned enterprises (SOEs) in the Chinese economy, in 2008 the State-owned Assets Supervision
and Administration Commission of the State Council (SASAC) released the Guidelines for SOEs in
terms of CSR interpretation and implementation [40]. In 2016 the SASAC further promulgated the
“Guide on the SOEs’ improved CSR performance” to explicitly elaborate the importance and the role
of CSR [41].
Regarding the CSR regulation in Chinese stock markets, the Shenzhen Stock Exchange (SZSE)
was the first to launch the “Guide on Listed Companies’ Social Responsibility” in 2006, promoting
voluntary disclosure of CSR reports and advising periodic analysis of CSR performance. In 2008,
the Shanghai Stock Exchange (SHSE) released the “Guide on Listed Companies’ Environmental
Information Disclosure”, requiring the following three types of listed companies that need to disclose
CSR reports annually if they are in the Corporate Governance Index, simultaneously listed in the
domestic and foreign stock markets, or are operating in the financial sector. Based on this criterion,
797 companies listed in SHSE published CSR reports in 2018, and about 278 of them were voluntary
disclosures [42]. The number of CSR and voluntary reports is much higher than 2008, which merely
contained 290 reports and 32 voluntary disclosures.
2.3. Stakeholder Theory in Explaining CSR Dimensions
The pressure exerted by different stakeholders’ influences corporate decisions about whether or
not to implement CSR practices [9]. Actively responding to stakeholders’ concerns is essential for
an enterprise to gain a competitive advantage [43,44]. Specifically, the stakeholder theory suggests
that companies can cause externalities to various parties that have vested interests or “stakes” in the
organization. These parties can be internal or external to corporate operations including employees,
customers, suppliers, government, and community [25]. As a result of externalities connected with
stakeholders, companies are pressured to mitigate adverse effects on society, such as preventing
environmental pollution and improving positive image through socially responsible activities, such as
charitable donations and community involvement. Therefore, stakeholder theory can explain the
motivation of CSR and mainly how a company assigns its organizational resources to manage the
relationship with stakeholders, aiming to improve their welfare [6].
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According to the classification put forward by Donaldson and Preston [45], stakeholder theory can
be interpreted as having three aspects that are descriptive, instrumental, and normative. These distinct
perspectives of stakeholder theory offer a lens to observe the adoption of CSR and organizational
changes based on stakeholder management. For example, the descriptive approach depicts the
ways the companies are practicing CSR in terms of stakeholders’ interests. The normative approach
describes the reason for CSR adoption, specifically focusing on the moral and philosophical aspects.
The instrumental approach explains the performance achievement by managing the relationship
with stakeholders. In particular, the instrumental aspect of the stakeholder model explores whether
a company can benefit from CSR practices with a combination of stakeholders’ needs and social
trustworthiness that can acquire competitive advantages by maximizing firm value [46]. In a nutshell,
it provides a clue to investigate the connection between CSR practices and the fulfillment of corporate
objectives such as profitability and sustainable growth.
Many prior studies empirically examined the association between CSR and firm performance in the
light of stakeholder theory. Maignan et al. [43] revealed that CSR practices measured by a 5-point scale
scoring by external experts have a positive association with financial performance measured by return
on assets (ROA), return on investment (ROI), profit growth, and sales growth. Likewise, an empirical
investigation of 61 funds from socially responsible investments (SRI) from 1972–2000 shows that CSR
practices can improve the average monthly return of SRI funds [47]. Recently, a study investigated the
effect of firm visibility on the association between CSR and corporate financial performance in Taiwan,
and suggested that firms with better CSR performance can obtain financial results superior to those of
firm which would not pursue CSR initiatives. [48]. In the context of the U.S, the largest firms ranked by
Newsweek in 2009 demonstrate that CSR can promote financial performance measured by cumulative
abnormal returns [9]. From the Chinese perspective, Chen and Wang [36] defined nine types of
stakeholders for Chinese enterprises and empirically found that CSR activity can improve financial
performance in the current and following year. Subsequently, the data of Chinese national state-owned
enterprises (CNSOEs) was examined by Zhu et al. [4]. Their results suggest that CSR practices related
to aspects of labor practices, community involvement, supply chain, and political responsibility are
positively associated with annual operating performance. Freeman [25] delineates that customers,
employees, and suppliers directly influence enterprises, while government, environment, and society
indirectly affect companies’ performance and operations. The stakeholder theory stresses a necessity
for firms to actively engage in CSR practices because they can bring benefits to the companies.
2.4. Hypotheses Development
Chinese firms may experience difficulties in achieving sustainable financial performance without
effectively promoting CSR practices [49]. Put differently, engaging in CSR activities helps companies to
effectively manage the relationship with their stakeholders, who can create, develop, and maintain
the link with productive resources [50]. From the perspective of stakeholders, CSR practices enhance
their commitment to a firm’s operations [51]. The ways Chinese enterprises socially deal with their
stakeholders is a key feature to ensure a continued concern [4]. Based on the above discussion; we put
forward our first hypothesis to examine whether CSR practices can yield financial returns for Chinese
pharmaceutical companies:
Hypothesis 1 (H1). In the Chinese context, pharmaceuticals’ overall CSR efficiency can increase
firm performance.
The descriptive aspect of stakeholder theory enables us to identify different groups of stakeholders
that are connected to firms’ CSR efforts. Shareholders are one of the primary stakeholders because of
their close association with corporate strategy and operations [52]. Firms would gain financial returns
if their financially responsible activities are acknowledged by shareholders and potential investors.
Pharmaceuticals are particularly responsible for promoting employees’ benefits to periodically perform
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health and safety checks due to the higher risks in the process of new product development,
manufacturing, and recycling [16]. The supportive attitude towards employees enables companies to
attract, retain, and motivate valuable human resources, resulting in lower turnover rate and higher
productivity [53]. Given the increased global production and marketing activities, CSR activities
have been extended to supply chain management and product safety maintenance. Especially, drugs
are directly associated with human health and well-being, while the high-quality of raw materials
and medicines can enhance customer loyalty towards pharmaceuticals along with higher financial
gains [52,54]. In addition, pharmaceutical companies would regard the environment as an important
aspect of their CSR strategy because their negative impacts on the local environment, such as medical
disposals and discharges, may be fined by authorities, resulting in substantial short-term costs [55].
Wu et al. [56] argue that environmentally friendly CSR activities promote innovation in Chinese firms
through public visibility and firm transparency. Jiang and Akbar [57] reveal that in China’s context
female executives tend to make a relatively higher amount of environmental protection investments.
However, it still remains unclear how green CSR activities advance financial performance of firms.
To portray themselves as social citizens, pharmaceuticals are expected to support the local community
by promoting health-care education and development, which enable such companies to lobby for tax
reductions or preferential policies by the government [52,58]. Thus, based on the above discussion,
our second hypothesis examine whether various CSR dimensions of stakeholders enhance financial
gains in Chinese Pharmaceuticals.
Hypothesis 2 (H2). In the context of China, pharmaceuticals’ favorable CSR practices concerning various
stakeholders (shareholders, employees, customers, and suppliers, the environment and society, respectively) can
increase firm performance.
3. Research Design
3.1. Sample Selection
The sample for this study consists of pharmaceutical companies listed on the Shanghai and
Shenzhen stock exchange. The data of CSR is collected from the Hexun CSR database, which is one of
the biggest third-party rating systems in China that provide specialized information about firms’ social
performance drawn from 38 indicators under five dimensions. Hexun CSR ratings are widely employed
as a valid proxy in measuring CSR performance of Chinese enterprises since 2010 [52,59]. The data
of firm performance was obtained from the China Stock Market and Accounting Research (CSMAR)
database. Given the integration of Hexun CSR data into CSMAR, we further exclude observations that
are labeled as “Special Treatment (ST)” by China’s Securities Regulatory Commission as companies
experiencing abnormal financial conditions for consecutive years. Our final sample comprises 875
firm-year observations over 7 years between 2010 and 2016. A list of the sample pharmaceutical
companies is provided in Appendix A.
3.2. Variables of the Study
CSR
CSR is the independent variable of this study. The measurement of CSR is carried out by obtaining
data from the Hexun CSR rating [60], which is a top-ranked rating agency that provides professional
financial and CSR information of listed companies on the basis of user satisfaction. Hexun was
founded in 1996 and launched the CSR evaluation database in 2010. Both the social responsibility
reports and the annual reports are assessed by Hexun based on the framework of stakeholder theory.
CSR performance is evaluated through five dimensions of stakeholders, comprising shareholders,
employees, suppliers and customers, the environment, and society, respectively. These five dimensions
include 13 s-class indices and 38 third-class indices [60]. By employing criteria from the Hexun rating
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system, our study assesses overall CSR score and score of each stakeholders’ dimension, ranging from 0
to 100 as presented in Table 2.
Table 2. Hexun CSR evaluation framework.
Dimension of CSR Performance Second-Class Measures Third-Class Measures
Shareholders (weight ratio: 30%)
Profitability (10%)
ROE (2%)
ROA (2%)
Return of sales (2%)
Cost margin (1%)
EPS (2%)
Retained earnings per share (1%)
Debt paying (3%)
Quick ratio (0.5%)
Liquidity ratio (0.5%)
Cash ratio (0.5%)
Equity ratio (0.5%)
Asset-liability ration (1%)
Return (8%)
Dividend capital ratio (2%)
Dividend yield (3%)
Bonus share allocation ratio of profit (3%)
Credit (5%) Number of penalties by stock exchange (5%)
Innovation (4%)
R & D expenditure (1%)
Concept of technological innovation (1%)
The number of items of technological innovation (2%)
Employees (weight ratio: 15%, 10% in consumption
sector)
Performance (5%) Per capita incomes of workers (4%)
Training of staff (1%)
Safety (5%) Periodic security check (2%)
Safety training (3%)
Caring for employees (5%)
Policy of caring (1%)
Number of caring (2%)
Caring payments (2%)
Customers and suppliers (weight ratio: 15%, 10% in
consumption sector)
Product quality (7%) Policy of quality management (3%)
Quality management system certificate (4%)
Customer service (3%) Customer satisfaction survey (3%)
Mutual good faith (5%) Vendor fair competition (3%)
Anti-bribery training (2%)
Environment (weight ratio: 20%, 30% in
manufacturing sector, 10% in service sector)
Environmental governance
(20%)
Policy of environmental protection (2%)
Environmental management system certificate (3%)
Environmental investment amount (5%)
Number of types of sewage (5%)
Number of types of green energy (5%)
Society (weight ratio: 20%, 30% in service sector, 10%
in manufacturing sector) Contribution (20%)
Tax (10%)
Donation amount (10%)
Specifically, the Hexun CSR rating adopts a weighted sum from the first-class five dimensions to
the third-class indices in order to compose overall CSR score. The 38 third-class indices are assigned by
Hexun rating staff members, where both mathematical computations and qualitative judgment are used.
In terms of the numerical indicators, such as quick ratio in shareholder dimension and environmental
investment amount in the environment dimension, the score is assigned based on Hexun’s own data
models. Regarding the qualitative indicators, such as the policy of quality management in customer
and supplier dimension, the score is determined according to the rating staff’s discretion about whether
CSR reports disclose relevant items and include sufficient details. If no item is disclosed, then the
score is 0. As such, the score of third-class indices is normalized for obtaining second-class indices.
These values are subsequently multiplied by the corresponding weight. The resulting sum provides
the overall CSR score.
Prior literature contends that only the Hexun CSR rating provides an appropriate data source
for assessing the CSR of Chinese listed companies [61]. Though RKS CSR rating is also another
source frequently used in China [62]. However, according to a comparative study by Zhong et al. [63],
Hexun criteria are more robust for measuring CSR performance than RKS which is primarily concerned
with CSR reporting quality. In addition, Hexun CSR scoring is more objective because the evaluation is
mainly based on the numerical calculation of specific indices, rather than content analysis like RKS
CSR rating. Therefore, in the Chinese context, the Hexun rating system has been more commonly used
in the performance evaluation of CSR activities of enterprises [64,65].
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As per the Hexun criteria, the overall CSR score for a specific pharmaceutical firm may be calculated
as the following equation:
CSR score = 30%CSR(SHA) + 30% CSR(EMP) + 15%CSR(CUST & SUP) + 15%CSR(ENV) + 10%CSR(SOC), (1)
where CSR(SHA), CSR(EMP), CSR(CUST & SUP), CSR(ENV), and CSR(SOC) are corporate fulfillment
towards the CSR dimensions of shareholders, employees, customers and suppliers, the environment,
and society respectively. The score of each dimension, as well as the overall CSR score, were directly
extracted from Hexun CSR rating.
3.3. Firm Performance and Other Control Variables
As measures of firm performance, Orlitzky et al. [28] proposed three aspects that are market-based,
accounting-based, and perpetual-based. As McGuire et al. [66] point out, solely focusing on a single
aspect may lead to individual bias. For example, market-based measures only consider market
factors and they are vulnerably impacted by macroeconomic fluctuations [67], whilst accounting-based
measures regard the historical perspective of an enterprise, subject to only past financial information [68].
To eliminate individual bias we included both market-based and accounting-based measures in this
study. In this regard, we used Tobin’s Q as a proxy of market-based measure, and return on assets
(ROA), return on equity (ROE), and earnings per share (EPS) as proxies of accounting-based measures.
For a control variable, we used the natural logarithm of total assets to modulate the size of the sample.
The details of variables measurements are shown in Table 3.
Table 3. Constructs of the variables.
Variables Measurement
CSR-SHA CSR performance on shareholders dimension was extracted from Hexun CSR database.
CSR-EMP CSR performance on employees dimension was extracted from Hexun CSR database.
CSR-CUST & SUP CSR performance on customers and suppliers dimension was extracted from Hexun CSR database.
CSR-ENV CSR performance on the environment dimension was extracted from Hexun CSR database.
CSR-SOC CSR performance on society’s dimension was extracted from Hexun CSR database.
CSR The sum of score of five CSR dimensions extracted from Hexun CSR database
Tobin’s Q Tobin’s Q = total market value of firm/total assets value of firm
ROA Return on assets = net income/total average assets
ROE Return on equity = net income/total average equity
EPS Earnings per share = (net income − preferred dividends)/weighted average shares outstanding
LNTA Natural logarithm of total assets
4. Results and Discussions
4.1. Descriptive Statistics
The descriptive statistics of all variables are shown in Table 4. The mean and median value of
CSR is 29.52 and 24.75 respectively, indicating that Chinese pharmaceuticals in our sample carry a
relatively low CSR rating score, on a spectrum between 1 to 100. The standard deviation of CSR is
17.84, demonstrating that CSR performance appears quite differently across sample firms.
Meanwhile, the mean and median value of the shareholders’ dimensions of stakeholders’
responsibility (CSR-SHA) is 54.17 and 57.57, respectively, suggesting that sample companies attach
great importance to shareholders’ interests, compared to other dimensions. In particular, the negatively
skewed distribution of CSR-SHA indicates that most of Chinese pharmaceuticals in our sample obtained
lower than average score on shareholders’ responsibility fulfillment. Comparing with CSR-SHA,
society’s dimension (CSR-SOC) and employees’ dimension (CSR-EMP) of stakeholders’ responsibility
has lower mean values of 30.79 and 22.87, and median values of 28.35 and 12.30, respectively.
Regarding customers’ and suppliers’ dimensions (CSR-CUST & SUP) and the environmental aspect
(CSR-ENV) of stakeholders’ responsibility, the mean value is merely 14.56 and 10.40, respectively.
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It indicates that pharmaceutical firms have the lowest CSR score on environment as compared to other
dimensions. Specifically, both CSR-CUST & SUP, and CSR-ENV have zero median value, suggesting
that on average, the sample firms fail to undertake due responsibility towards environmental protection,
product safety, and suppliers’ satisfaction.
Table 4. Descriptive statistics.
Variables No. of Observations Median Mean Min. Max. S.D. Skewness
Tobin’s Q 875 2.689 3.242 0 16.854 2.232 1.798
ROA 875 0.660 0.069 −0.298 0.494 0.641 0.204
ROE 875 0.095 0.106 −0.911 6.918 0.256 21.848
EPS 875 0.417 0.550 −1.148 4.100 0.593 1.960
CSR 875 24.7500 29.5180 −11.4600 87.2200 17.8389 1.2651
CSR-SHA 875 57.567 54.174 −11.433 92.333 20.466 −0.749
CSR-EMP 875 12.300 22.874 0 100.000 26.016 1.582
CSR-CUST & SUP 875 0 14.560 0 100.000 32.215 1.809
CSR-ENV 875 0 10.400 0 100.000 23.642 2.026
CSR-SOC 875 28.350 30.789 −50.000 85.000 16.489 −0.431
LNTA 875 21.669 21.716 19.032 25.0187 1.002 0.143
Overall, our results indicate that although Chinese pharmaceutical firms have begun to realize
their responsibility towards stakeholders and the environment, they are yet to achieve a satisfactory
level of CSR performance. Moreover, shareholders are regarded as the most important stakeholders by
Chinese pharmaceuticals to attain sustainability.
The correlation matrix for the dependent and independent variables is demonstrated in Table 5.
The coefficients between all variables of firm performance are found to be significant at 0.01 level
except Tobin’s Q, indicating that the firms with higher accounting performance have better CSR
performance than their counterparts. In addition, all CSR dimensions are positively correlated with
accounting-based performance measures of ROA, ROE, and EPS. Though, Tobin’s Q, the proxy of
market-based performance, is not significantly associated with overall CSR indicator and individual
stakeholders’ dimensions except for shareholders dimension.
Table 5. Correlation analysis.
Tobin’s Q ROA ROE EPS LNTA CSR CSR-SHA CSR-EMP CSR-CUST& SUP CSR-ENV CSR-SOC
Tobin’s Q 1
ROA 0.350 ** 1
ROE 0.091 ** 0.483 ** 1
EPS 0.072 * 0.616 ** 0.260 ** 1
LNTA 0-.380 ** 0.067 * 0.015 0.326 ** 1
CSR −0.024 0.377 ** 0.032 * 0.424 ** 0.294 ** 1
CSR-SHA 0.155 ** 0.693 ** 0.222 ** 0.590 ** 0.272 ** 0.610 ** 1
CSR-EMP 0.003 0.248 ** 0.164 ** 0.309 ** 0.226 ** 0.879 ** 0.330 ** 1
CSR-CUST & SUP 0.006 0.216 ** 0.142 ** 0.240 ** 0.197 ** 0.911 ** 0.289 ** 0.912 ** 1
CSR-ENV −0.015 0.199 ** 0.114 ** 0.247 ** 0.205 ** 0.902 ** 0.286 ** 0.883 ** 0.964 ** 1
CSR-SOC −0.080 * 0.114 ** 0.075 * 0.097 ** 0.135 ** 0.499 ** 0.157 ** 0.298 ** 0.332 ** 0.335 ** 1
Notes: * p < 0.05, ** p < 0.01,*** p < 0.001.
4.2. Overall CSR and Firm Performance
To examine the relationship between CSR and firm performance, we regress firm performance on
the overall score of CSR and other control variables using the following regression model:
Firmper f ormanceit = β0 + β1CSRit + β2LNTAit + εit, (2)
where, Firmperformanceit is the performance of firm i in year t, which is measured by accounting-based
proxies of ROA, ROE, and EPS and market-based proxy such as Tobin’s Q. CSRit is the CSR score
of firm i in year t. As discussed in Research Design, the CSR score is obtained from the Hexun CSR
database. LNTAit is the nature logarithm of total assets of firm i in year t, and εit is the disturbance
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term. Based on Hypothesis 1, we expect the coefficient β1 to be positive and statistically significant
with firm performance.
Considering the structure of our data, a panel-based regression model is employed to control the
unobserved heterogeneity in the proposed model. The Likelihood test is applied at first to examine
whether fixed effects exist or not. Subsequently, Hausman test is used to choose between fixed-effects and
random-effects. The outcome suggests that fixed-effects is the appropriate specification in examining
the relationship between CSR with Tobin’s Q, and CSR with ROA and EPS. The random-effects model
is employed in examining the relationship between CSR with ROE based on the outcome of the
Likelihood test.
Regression results are demonstrated in Table 6. CSR has a significant coefficient with (p < 0.05)
ROA, ROE, and EPS. These results indicate that an increase in CSR score enables firms to enhance their
accounting performances. However, the model depicts that the coefficient between CSR and Tobin’s
Q is significantly negative. Suggesting that in China’s context, positive CSR practices hardly help
pharmaceuticals improve market performance. On the whole, the results of above models are consistent
with our first hypothesis which claims that engagement in CSR activities increases firm performance.
These findings are in line with the previous research investigating CSR and firm performance in
China [69].
Table 6. Panel-based regression models: CSR as the independent variable.
Dependent Variables
Tobin’s Q ROA ROE EPS
Independent
variable
CSR −0.0345 *** 0.0009 *** 0.0033 * 0.0059 ***
Control variable
Size −2.2433 *** −0.0071 −0.1025 *** 0.1051 **
Constant 51.1818 *** 0.1981 2.2582 *** −1.9091 *
Adjusted R2 0.6523 0.5296 0.3973 0.6707
F-statistics 12.8926 *** 8.3383 *** 7.0462 *** 14.2751 ***
Durbin–Watson 2.2095 1.8129 2.3988 1.1661
Notes: * p < 0.05, ** p < 0.01, *** p < 0.001.
The instrumental aspect of stakeholder theory enables to explain the positive association between
CSR and firm performance. The theory attempts to investigate the benefit of CSR activities by
incorporating the demands of stakeholders and social trustworthiness. Engaging in CSR related
endeavors assist Chinese pharmaceuticals to maintain sound relationships with key stakeholders,
who can create, develop, and maintain link to strategic resources [50]. Particularly, some resources
are difficult to acquire or duplicate by the rivals that can be counted as a competitive advantage of a
firm. Accordingly, firm performance can be enhanced through active externalities with stakeholders
accessed by the CSR practices.
4.3. Impact of Individual CSR Dimensions on Firm Performance
To further investigate the effects of a particular CSR dimension of stakeholders on firm performance,
we regress firm performance with shareholders dimension, employees dimension, customers and
suppliers dimension, the environment dimension and society’s dimension, respectively. The model
specification is presented below:
Firmper f ormanceit = β0 + β1StakeholdersDimensionit + β2LNTAit + εit (3)
where, StakeholdersDimensionit is performance of stakeholders’ practices of firm i in year t, which are
denoted as CSR-SHA, CSR-EMP, CSR-CUST & SUP, CSR-ENV, and CSR-SOC, respectively. As proposed
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in Hypothesis 2, we expect the relationship between each dimension of stakeholders and firm
performance to be positive and statistically significant.
We regress accounting performance proxies with each individual dimension in a panel-based
regression setting. The results of the Hausman test imply that the dimensions of shareholders
(CSR-SHA), employees (CSR-EMP), customers and suppliers (CUST & SUP), and the environment
(CSR-ENV) are appropriate in a fixed-effects model when examining the relationship with Tobin’s Q,
ROA, and EPS. However, the random-effects model is appropriate to observe the relationship with
ROE. Likewise, for the society dimension of CSR, a random-effects model is used in examining the
relationship with Tobin’s Q. The fixed-effects specification is adopted to examine the association with
ROA and EPS, whereas the pooled model is developed to test the association with ROE.
The results of the panel-based models concerning different CSR dimensions of stakeholders are
shown in Table 7. Specifically, the shareholders dimension has a positive significant (p < 0.05) coefficient
with Tobin’s Q, ROA, ROE, and EPS. These results depict that the efforts to promote shareholders’
welfare yield higher market-based and accounting-based performance for Chinese pharmaceuticals.
Hence, CSR practices help firms to promote shareholder trust and attract new investors who are
sensitive toward companies’ CSR activities, thus leading to better financial performance. These findings
are consistent with the previous research [47,54].
Table 7. Panel-based regression models: CSR dimensions as the independent variables.
Dependent Variables
Tobin’s Q ROA ROE EPS
Independent Variable
Shareholders (CSR-SHA) 0.0038 ** 0.0016 *** 0.0026 *** 0.0105 ***
Employees (CSR-EMP) −0.0017 0.0001 *** 0.0012 *** 0.0005 *
Customers and suppliers (CSR-CUST & SUP) −0.0014 0.0001 ** 0.0008 *** 0.0001
The environment (CSR-ENV) −0.0016 0.0001 ** 0.0009 *** 0.0002
Society (CSR-SOC) −0.0023 0.0001 ** 0.0004 *** 0.0010
Notes: * p < 0.05, ** p < 0.01, *** p < 0.001.
Table 7 also illustrates that a positive significant (p < 0.05) relationship exists between the
employees dimension of CSR and the firm’s accounting performance measures. Given that the Labor
Contract Law was enacted nation-wide [70], the protection of employees’ rights has witnessed a
considerable improvement in China. Promoting sound labor practices assist companies to attract,
retain, and motivate employees. Turnover rate may also decrease, hence leading to an increase in
productivity [53]. Overall, our results confirm that CSR efforts to promote labor protection help Chinese
pharmaceuticals to improve financial performance.
Similarly, the customers and suppliers dimension of CSR has a significant (p < 0.05) and positive
association with ROA and ROE. This empirical outcome is in line with [54] and [52], which emphasizes
that providing high-quality products and services enables firms to differentiate themselves from
competitors and build strong customer loyalty. Likewise, establishing trust and fairness with suppliers
help firms to reduce the cost of defective goods during the procurement process. Therefore, promoting
better CSR practices with customers and suppliers is positively associated with firm performance.
The environment aspect of CSR has received enormous attention from the public and the Chinese
government in recent years and the results are shown in Table 7 and indicates that the environmental
dimension of the firm’s CSR activities significantly (p < 0.05) and positively link with both ROA
and ROE. The promising CSR activities regarding environmental preservation and protection enable
companies to receive approval of the relevant regulatory authorities. Therefore, such firms benefit from
lower operating costs incurred through insurance and fines concerning environmental degradation [55].
The environment-related CSR efforts assist companies to act as responsible corporate citizens and
attract more attention form environment-sensitive investors.
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The last dimension of CSR practices towards society is found to be significantly (p < 0.05) and
positively associated with ROA and ROE. These results assert that actively contributing to social
activities, such as community development and charitable donations creates an overall positive
image of an enterprise. Moreover, it enables firms to lobby for tax concessions and other financial
benefits [47,71]. Besides, promoting corporate citizenship through proactive social activities help firms
to negotiate for favorable policies with the government to attain reasonable profitability.
Overall, the above regression models positively relate CSR dimensions with enterprise
performance, thus support the hypothesis of this study which proposes that a particular aspect
of CSR positively contributes to a firm’s financial performance. These findings corroborate with the
instrumental aspect of stakeholder theory which proposes that a firm can benefit from CSR activities
by effectively responding to its stakeholders’ demands. Efficient stakeholder management enables
Chinese pharmaceuticals to mitigate adverse effects on society. Specifically, sound labor relations can
lower hiring costs and ameliorate productivity [53]. Likewise, a favorable social image helps to gain
positive goodwill that can buffer a pharmaceutical from unanticipated problems. Moreover, such
practices can pave the way for valuable opportunities that are not available to poor CSR firms [4].
Therefore, actively responding to various groups of stakeholders can bring out competitive advantages
to an enterprise, consequently resulting in superior economic returns.
5. Conclusions
This study was set out to investigate whether CSR efforts enhance firm performance in the context
of pharmaceutical companies in China. Based on the stakeholder theory and the CSR stakeholder
framework outlined by the Hexun CSR database, we develop five CSR dimensions to measure various
aspects of CSR performance, and incorporate them to measure the overall CSR score. By examining CSR
practices between 2010 and 2016 among 125 Chinese pharmaceutical companies we conclude that CSR
helps to improve firm’s financial performance. Moreover, all of the five CSR dimensions identified in
the study relates positively to firm performance. However, the results suggest that the environment is
regarded as the most critical CSR dimension to optimize firm performance. This outcome is attributed
to the stringent environmental regulations promulgated by the Chinese government in recent years.
Whereas, the score on society dimension slightly lags behind other dimensions of CSR.
As a matter of fact, many Chinese firms hesitate to actively participate in CSR activities as they
dread that such practices may not promote firm profitability or performance in the stock market.
However, the empirical outcomes of this study suggest that CSR endeavors can yield sustainable
firm performance. Specifically, CSR activities assist companies to maintain good relations with key
stakeholders by creating a favorable perception of their operations. Hence such firms can establish a
strong brand image and customer loyalty which can serve as a competitive advantage. Consequently,
revenue and market share leads to better financial performance.
The extant literature predominantly focused on the CSR practices of advanced countries.
Nevertheless, emerging economies have an underdeveloped CSR framework which makes it interesting
to see how CSR activities impact firm performance in emerging markets like China. Furthermore, in the
backdrop of numerous health- and environment-related incidents reported in Chinese pharmaceutical
companies in recent years we chose the pharmaceutical industry as our research sample. Thus extending
the previous research on CSR which does not specialize in a particular sector. In addition, unlike
previous studies, which take the overall CSR score to assess a firm’s CSR performance, we empirically
tested the impact of each individual dimension of CSR on the financial performance of Chinese
pharmaceuticals. Hence, we provide more extensive insight into the multifaceted CSR endeavors.
Our findings have several practical implications. First, given the poor CSR performance and
practices regarding the environment dimension, Chinese pharmaceutical firms need to step up efforts to
promote environment-related socially responsible activities. Second, the positive association between
CSR and firm performance should also motivate companies to realize promising financial gains through
CSR enforcement. Hence, CSR practices should be embedded within the firm’s planning, controlling,
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and decision-making process. Third, Chinese regulators need to implement rigorous CSR regulations.
For instance, the government can impose heavy fines in case of CSR violations. The monetary incentives
such as tax breaks and the granting of subsidies to firms with exceptional CSR performance can also be
introduced to achieve this goal.
Though, the study is not without limitations. First, we did not account for the impact of the
business cycle on the proposed relationship between CSR indicators and firm performance. Second, the
effect of time lag can be employed in the analysis to see how a change in a firm’s performance reflects
in later years with a corresponding change in CSR practices. Further studies can incorporate such
factors to extend this line of research.
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Appendix A
Table A1. Sample pharmaceutical companies.
S/N Code Name of the Company S/N Code Name of the Company
1 000004 CAU Technology 64 300049 Fu-rui Pharmaceutical
2 000078 Neptunus Group 65 300110 Huaren Pharmaceutical
3 000153 BBCA Pharmaceutical 66 300119 Ruipu Biological
4 000403 Shenghua Pharmaceutical 67 300122 Zhifei Biological
5 000423 Dongeejiao Group 68 300138 CCGB Biological
6 000513 Livzon Pharmaceutical 69 300142 Walvax Biotechnology
7 000518 Sihuan Biological 70 300158 Zhengdong Group
8 000538 Yunnai baiyao 71 300181 Zuoli Pharmaceutical
9 000545 Jinpu Group 72 300194 Fuan Pharmaceutical
10 000590 Guhan Group 73 300199 Hanyu Biological
11 000597 Northeast Pharmaceutical 74 300204 Staidson Bio-pharmaceutical
12 000606 Shenzhou Yiqiao 75 300239 Dongbao Biological
13 000623 Jilin Aodong Medical 76 300254 CY Pharmaceutical
14 000650 Renhe Pharmaceutical 77 300255 CSBIO Group
15 000661 Changchun Gaoxin 78 300267 Erkang Pharmaceutical
16 000739 Apeloa Pharmaceutical 79 300289 Leadman Biological
17 000756 Xinhua Pharmaceutical 80 300294 Boya Pharmaceutical
18 000766 Tonghua Jinma 81 600062 DCPC Pharmaceutical
19 000788 PKU Health care 82 600079 HumanWell Healthcare
20 000915 Sd-Wit Group 83 600129 Taiji Group
21 000919 Jinlin Pharmaceutical 84 600161 Tiantan Biological
22 000952 Guangji Pharmaceutical 85 600195 CAHIC Group
23 000989 JZT Pharmaceutical 86 600196 Fosun Pharmaceutical
24 000990 Chengzhi Group 87 600201 Jinyu Bio-technology
25 000999 999 Pharmaceutical 88 600211 Tibet Pharmaceutical
26 002001 NHU group 89 600222 Tailong Pharmaceutical
27 002004 Huapont Life Science 90 600252 Zhongheng Group
28 002007 Hualan Biological 91 600267 Hisun Pharmaceutical
29 002020 Jinxin Pharmaceutical 92 600276 Hengrui Medicine
30 002022 Kehua Biological 93 600285 Lingrui Pharmaceutical
31 002030 Daan Gene 94 600329 Zhongxin Pharmaceutical
32 002038 Shuanglu Pharmaceutical 95 600332 BYS Pharmaceutical
33 002099 Hisoar Pharmaceutical 96 600351 Yabao Pharmaceutical
34 002107 Wohua Pharmaceutical 97 600380 Joincare
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Table A1. Cont.
S/N Code Name of the Company S/N Code Name of the Company
35 002118 Zixin Pharmaceutical 98 600420 Shyndec Pharmaceutical
36 002166 Layn Biological 99 600422 KPC Pharmaceutical
37 002198 Jiaying Pharmaceutical 100 600436 Pien Tze Huang
38 002219 Hengkang Medical 101 600466 BRC Group
39 002252 Shanghai RAAS 102 600479 Qianjin Pharmaceutical
40 002275 Sanjin Pharmaceutical 103 600488 Tianyao Pharmaceutical
41 002287 Cheezheng Pharmaceutical 104 600513 Lianghuang Group
42 002294 Salubris Pharmaceutical 105 600518 Kangmei Pharmaceutical
43 002317 ZS Pharmaceutical 106 600521 Huahai Pharmaceutical
44 002332 Xianju Pharmaceutical 107 600530 Onlly Group
45 002349 Jinghua Pharmaceutical 108 600535 Tasly Group
46 002370 Yatai Pharmaceutical 109 600557 Kanion Pharmaceutical
47 002393 Lisheng Pharmaceutical 110 600572 Conba Group
48 002399 Hepalink Pharmaceutical 111 600594 Yibai Pharmaceutical
49 002412 Hansen Pharmaceutical 112 600613 Shengqi Pharmaceutical
50 002422 Kelun Pharmaceutical 113 600664 Hayao Pharmaceutical
51 002424 Bailing Pharmaceutical 114 600671 HZTM Pharmaceutical
52 002433 Pibao Pharmaceutical 115 600750 Jiangzhong Pharmaceutical
53 002437 Gloria Pharmaceutical 116 600771 Guangyuyuan
54 002550 Qianhong Bio-pharma 117 600781 Furen Pharmaceutical
55 002566 Yisheng Pharmaceutical 118 600789 Lukang Pharmaceutical
56 002603 Yiling Pharmaceutical 119 600803 ENN Group
57 002644 Foci Pharmaceutical 120 600812 Huabei Pharmaceutical
58 002653 Haisco Pharmaceutical 121 600829 RMTT Pharmaceutical
59 300006 Laimei Pharmaceutical 122 600867 Dongbao Pharmaceutical
60 300009 Anke Biological 123 600869 Zhihui Group
61 300016 Beilu Pharmaceutical 124 600976 Jianmin Group
62 300026 Chasesun Pharmaceutical 125 600993 Mayinglong
63 300039 Kaibao Pharmaceutical
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